Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Olstein Capital Management L.P.

Olstein Capital Management L.P. reduced its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 25.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,000 shares of the company’s stock after selling 9,000 shares during the quarter. Olstein Capital Management L.P.’s holdings in Prestige Consumer Healthcare were worth $2,030,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of PBH. Exchange Traded Concepts LLC lifted its holdings in Prestige Consumer Healthcare by 4.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 23,776 shares of the company’s stock valued at $1,857,000 after acquiring an additional 975 shares during the period. Avior Wealth Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 1,570.7% in the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock valued at $668,000 after purchasing an additional 8,042 shares during the period. SG Americas Securities LLC boosted its holdings in Prestige Consumer Healthcare by 18.8% during the fourth quarter. SG Americas Securities LLC now owns 5,996 shares of the company’s stock worth $468,000 after buying an additional 947 shares in the last quarter. Diversify Wealth Management LLC grew its position in Prestige Consumer Healthcare by 35.3% during the fourth quarter. Diversify Wealth Management LLC now owns 10,399 shares of the company’s stock worth $770,000 after buying an additional 2,713 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Prestige Consumer Healthcare by 171.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 46,931 shares of the company’s stock worth $3,665,000 after buying an additional 29,649 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $76.79 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The business’s fifty day moving average price is $80.08 and its two-hundred day moving average price is $74.88. The stock has a market cap of $3.79 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.17 and a beta of 0.51. Prestige Consumer Healthcare Inc. has a one year low of $60.00 and a one year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same quarter last year, the company earned $1.07 earnings per share. The business’s revenue for the quarter was down .9% compared to the same quarter last year. On average, analysts forecast that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. This represents a 33.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 in the last ninety days. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

PBH has been the topic of several research analyst reports. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.